Literature DB >> 21029859

DNA damage-mediated induction of a chemoresistant niche.

Luke A Gilbert1, Michael T Hemann.   

Abstract

While numerous cell-intrinsic processes are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the tumor microenvironment on therapeutic outcome. Here, we use a well-established mouse model of Burkitt's lymphoma to show that paracrine factors in the tumor microenvironment modulate lymphoma cell survival following the administration of genotoxic chemotherapy. Specifically, IL-6 and Timp-1 are released in the thymus in response to DNA damage, creating a "chemo-resistant niche" that promotes the survival of a minimal residual tumor burden and serves as a reservoir for eventual tumor relapse. Notably, IL-6 is released acutely from thymic endothelial cells in a p38-dependent manner following genotoxic stress, and this acute secretory response precedes the gradual induction of senescence in tumor-associated stromal cells. Thus, conventional chemotherapies can induce tumor regression while simultaneously eliciting stress responses that protect subsets of tumor cells in select anatomical locations from drug action.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029859      PMCID: PMC2972353          DOI: 10.1016/j.cell.2010.09.043

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  39 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

Authors:  P Corradini; M Ladetto; A Pileri; C Tarella
Journal:  Leukemia       Date:  1999-11       Impact factor: 11.528

Review 3.  Transcriptional control of the inflammatory response.

Authors:  Ruslan Medzhitov; Tiffany Horng
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

Review 4.  New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

Authors:  K D Holen; L B Saltz
Journal:  Lancet Oncol       Date:  2001-05       Impact factor: 41.316

5.  Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1.

Authors:  M Jourdan; J De Vos; N Mechti; B Klein
Journal:  Cell Death Differ       Date:  2000-12       Impact factor: 15.828

6.  Circulating interleukin-6 predicts survival in patients with metastatic breast cancer.

Authors:  Roberto Salgado; Sara Junius; Ina Benoy; Peter Van Dam; Peter Vermeulen; Eric Van Marck; Philippe Huget; Luc Y Dirix
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

7.  High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B.

Authors:  Vincent Wai-Sun Wong; Jun Yu; Alfred Sze-Lok Cheng; Grace Lai-Hung Wong; Hoi-Yun Chan; Eagle Siu-Hong Chu; Enders Kai-On Ng; Francis Ka-Leung Chan; Joseph Jao-Yao Sung; Henry Lik-Yuen Chan
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

8.  Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival.

Authors:  Elise Lambert; Cédric Boudot; Zahra Kadri; Mahdhia Soula-Rothhut; Marie-Line Sowa; Patrick Mayeux; William Hornebeck; Bernard Haye; Emmanuelle Petitfrere
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

9.  Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

Authors:  Nikolaos Xenidis; Michail Ignatiadis; Stella Apostolaki; Maria Perraki; Kostas Kalbakis; Sofia Agelaki; Efstathios N Stathopoulos; Grigorios Chlouverakis; Evi Lianidou; Stylianos Kakolyris; Vassilis Georgoulias; Dimitris Mavroudis
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

Review 10.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence.

Authors:  Mohit Trikha; Robert Corringham; Bernard Klein; Jean-François Rossi
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

View more
  186 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

2.  Cancer: Chemotherapy counteracted.

Authors:  Urban Emmenegger; Robert S Kerbel
Journal:  Nature       Date:  2010-12-02       Impact factor: 49.962

3.  A CXCL1 paracrine network links cancer chemoresistance and metastasis.

Authors:  Swarnali Acharyya; Thordur Oskarsson; Sakari Vanharanta; Srinivas Malladi; Juliet Kim; Patrick G Morris; Katia Manova-Todorova; Margaret Leversha; Nancy Hogg; Venkatraman E Seshan; Larry Norton; Edi Brogi; Joan Massagué
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

Review 4.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

Review 5.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

Review 6.  Tumor heterogeneity in the clinic: is it a real problem?

Authors:  Filip Janku
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 7.  Drug screening in Drosophila; why, when, and when not?

Authors:  Tin Tin Su
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2019-05-05       Impact factor: 5.814

8.  LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer.

Authors:  S Wang; Z Zou; X Luo; Y Mi; H Chang; D Xing
Journal:  Oncogene       Date:  2018-03-16       Impact factor: 9.867

Review 9.  The pan-therapeutic resistance of disseminated tumor cells: Role of phenotypic plasticity and the metastatic microenvironment.

Authors:  Bo Ma; Alan Wells; Amanda M Clark
Journal:  Semin Cancer Biol       Date:  2019-07-31       Impact factor: 15.707

Review 10.  Harnessing Tumor Evolution to Circumvent Resistance.

Authors:  Katherine L Pogrebniak; Christina Curtis
Journal:  Trends Genet       Date:  2018-06-11       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.